| Fang JY, Shen KL, Huang YB, Wu PC and Tsai YH |
------>authors3_c=None ------>paper_class1=1 ------>Impact_Factor=None ------>paper_class3=1 ------>paper_class2=1 ------>vol=14 ------>confirm_bywho=kyhsu ------>insert_bywho=??? ------>Jurnal_Rank=None ------>authors4_c=None ------>comm_author= ------>patent_EDate=None ------>authors5_c=None ------>publish_day=None ------>paper_class2Letter=None ------>page2=293 ------>medlineContent= ------>unit=G0100 ------>insert_date=19991209 ------>iam=1 ------>update_date= ------>author=??? ------>change_event=5 ------>ISSN=None ------>authors_c=None ------>score=500 ------>journal_name=Kaohsiung J. Med. Sci. ------>paper_name=Topical application of clobetasol 17-propionate from various cream bases by using Wistar rat as an animal model. ------>confirm_date=20010323 ------>tch_id=087003 ------>pmid=9619014 ------>page1=286 ------>fullAbstract=The effect of clobetasol 17-propionate (CP), a potent corticosteroid, participating in various cream bases on the permeation through rat skin was tested in vitro. Three commercially available formulations and three cream bases prepared in our laboratory according to Pharmacopoeia or registered patent were evaluated in this present study. The amount of CP in the receptor phase of diffusion cell was negligible in the beginning of administration due to the process of saturation of drug in skin reservoir, then the CP molecules pass through the skin directly because of the saturation of receptors in skin reservoir followed the higher flux of CP in the later period. It was suggested that the incorporation of penetration enhancers was the possible reason mainly controlling the flux of CP creams. Nevertheless, CP residue in skin and the lag time of formulations prepared in our laboratory were not significantly higher than those of commercial ones, which indicated penetration enhancer could not dominate the local pharmacological effectiveness of CP though they played a main part on the skin penetration capacity of formulations. The antiinflammatory activity of CP was assessed in the ear of Wistar rat. According to the result of antiinflammatory activity, all formulations showed significant inhibition on oedema suggesting the role of drug itself may be more important than that of vehicle in controlling the therapy efficacy. ------>tmu_sno=None ------>sno=270 ------>authors2=None ------>authors3=None ------>authors4=None ------>authors5=None ------>authors6=None ------>authors6_c=None ------>authors=Fang JY, Shen KL, Huang YB, Wu PC and Tsai YH ------>delete_flag=0 ------>SCI_JNo=None ------>authors2_c=None ------>publish_area=None ------>updateTitle=Topical application of clobetasol 17-propionate from various cream bases by using Wistar rat as an animal model. ------>language=2 ------>check_flag=0 ------>submit_date= ------>country=None ------>no= ------>patent_SDate=None ------>update_bywho= ------>publish_year=1998 ------>submit_flag= ------>publish_month=None |